LENSAR LNSR
LENSAR Q1 FY26: revenue $13.4M, down 5%; diluted EPS $0.00
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001193125-26-214571
Key figures from this report
These are the numbers LENSAR reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$13.4M−5% from $14.2M in Q1 FY2510-Q income statement, on EDGAR
- Net income$36.3MAgainst −$27.3M in Q1 FY2510-Q income statement, on EDGAR
- Diluted EPS$0.00Against −$2.32 in Q1 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$12.5M−36% from $19.5M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$4.3MAgainst −$6.9M in Q1 FY2510-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- CVRx CVRX public float $112M, Jun 30, 2025
- TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
- Shoulder Innovations SI
- KORU Medical Systems KRMD public float $119M, Jun 30, 2025
- Mobia Medical MOBI
